ATE321763T1 - 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino¬4, - bäindolacetamidderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung - Google Patents

3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino¬4, - bäindolacetamidderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung

Info

Publication number: ATE321763T1
Authority: AT; Austria
Prior art keywords: sub; bäindolacetamide; pyridazino; dihydro; heteroaryl
Prior art date: 2002-04-03

Application number

AT03730299T

Other languages

English (en)

Inventor

Jacques Cedex Froissant

Benoit Marabout

Frank Marguet

Frederic Puech

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-03

Filing date

2003-04-02

Publication date

2006-04-15

2003-04-02 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2006-04-15 Application granted granted Critical

2006-04-15 Publication of ATE321763T1 publication Critical patent/ATE321763T1/de

Links

238000000034 method Methods 0.000 title abstract 2
230000001225 therapeutic effect Effects 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 3
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
125000005843 halogen group Chemical group 0.000 abstract 2
239000002253 acid Substances 0.000 abstract 1
150000007513 acids Chemical class 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
150000004677 hydrates Chemical class 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
125000002757 morpholinyl group Chemical group 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000003386 piperidinyl group Chemical group 0.000 abstract 1
125000003373 pyrazinyl group Chemical group 0.000 abstract 1
125000002098 pyridazinyl group Chemical group 0.000 abstract 1
125000004076 pyridyl group Chemical group 0.000 abstract 1
125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Indole Compounds (AREA)

AT03730299T 2002-04-03 2003-04-02 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino¬4, - bäindolacetamidderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung ATE321763T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0204158A FR2838124B1 (fr)	2002-04-03	2002-04-03	Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique

Publications (1)

Publication Number	Publication Date
ATE321763T1 true ATE321763T1 (de)	2006-04-15

Family

ID=28052083

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03730299T ATE321763T1 (de)	2002-04-03	2003-04-02	3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino¬4, - bäindolacetamidderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung

Country Status (28)

Country	Link
US (4)	US7235554B2 (de)
EP (1)	EP1492792B1 (de)
JP (2)	JP4575670B2 (de)
KR (1)	KR100975999B1 (de)
CN (2)	CN100406459C (de)
AT (1)	ATE321763T1 (de)
AU (1)	AU2003240930B2 (de)
BR (1)	BR0309018A (de)
CA (1)	CA2481460C (de)
CY (1)	CY1104998T1 (de)
DE (1)	DE60304327T2 (de)
DK (1)	DK1492792T3 (de)
EA (1)	EA007219B1 (de)
ES (1)	ES2261940T3 (de)
FR (1)	FR2838124B1 (de)
HR (1)	HRP20040911B1 (de)
IL (2)	IL164257A0 (de)
IS (1)	IS2483B (de)
ME (2)	ME00081B (de)
MX (1)	MXPA04009635A (de)
NO (1)	NO329426B1 (de)
NZ (1)	NZ535741A (de)
PL (1)	PL372617A1 (de)
PT (1)	PT1492792E (de)
RS (1)	RS51244B (de)
UA (1)	UA77273C2 (de)
WO (1)	WO2003082874A2 (de)
ZA (1)	ZA200407945B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2577036A1 (en) *	2004-08-18	2006-02-23	Genesense Technologies Inc.	Small interfering rna molecules against ribonucleotide reductase and uses thereof
WO2007032854A1 (en) *	2005-08-19	2007-03-22	Schering Corporation	FUSED TRICYCLIC mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS
EP2391607A1 (de) *	2009-01-30	2011-12-07	AstraZeneca AB	Neues verfahren für die die zubereitung von carboxy-haltigen pyrazolamidverbidnungen 597
CN105330665B (zh) *	2015-11-04	2017-10-03	衡阳师范学院	一种抑制激肽释放酶klk7的化合物、制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2754262B1 (fr)	1996-10-08	1998-10-30	Synthelabo	Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
FR2766823B1 (fr) *	1997-07-30	1999-10-08	Synthelabo	Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) *	1999-01-26	2004-03-05	Synthelabo	Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR2788776B1 (fr) *	1999-01-26	2001-02-23	Synthelabo	Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique
FR2811897A1 (fr) *	2000-07-24	2002-01-25	Sanofi Synthelabo	UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1- ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AU TRAITEMENT DES DYSFONCTIONNEMENTS DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES
FR2811990A1 (fr) *	2000-07-24	2002-01-25	Sanofi Synthelabo	DERIVES DE 1-(4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1 -CARBONYL)PIPERAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2833953B1 (fr) *	2001-12-21	2004-12-03	Sanofi Synthelabo	DERIVES DE 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO [4,5-b]INDOLE-1-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

2002
- 2002-04-03 FR FR0204158A patent/FR2838124B1/fr not_active Expired - Fee Related
2003
- 2003-02-04 UA UA20041008012A patent/UA77273C2/uk unknown
- 2003-04-02 ME MEP-2008-237A patent/ME00081B/me unknown
- 2003-04-02 PT PT03730299T patent/PT1492792E/pt unknown
- 2003-04-02 ME MEP-237/08A patent/MEP23708A/xx unknown
- 2003-04-02 CN CNB038122227A patent/CN100406459C/zh not_active Expired - Fee Related
- 2003-04-02 KR KR1020047015629A patent/KR100975999B1/ko not_active Expired - Fee Related
- 2003-04-02 WO PCT/FR2003/001027 patent/WO2003082874A2/fr not_active Ceased
- 2003-04-02 HR HRP20040911 patent/HRP20040911B1/xx not_active IP Right Cessation
- 2003-04-02 RS YUP-869/04A patent/RS51244B/sr unknown
- 2003-04-02 US US10/509,695 patent/US7235554B2/en not_active Expired - Lifetime
- 2003-04-02 EP EP03730299A patent/EP1492792B1/de not_active Expired - Lifetime
- 2003-04-02 ES ES03730299T patent/ES2261940T3/es not_active Expired - Lifetime
- 2003-04-02 BR BR0309018-3A patent/BR0309018A/pt not_active IP Right Cessation
- 2003-04-02 AT AT03730299T patent/ATE321763T1/de active
- 2003-04-02 CN CNB2006101003182A patent/CN100543016C/zh not_active Expired - Fee Related
- 2003-04-02 CA CA2481460A patent/CA2481460C/en not_active Expired - Fee Related
- 2003-04-02 MX MXPA04009635A patent/MXPA04009635A/es active IP Right Grant
- 2003-04-02 EA EA200401146A patent/EA007219B1/ru not_active IP Right Cessation
- 2003-04-02 PL PL03372617A patent/PL372617A1/xx unknown
- 2003-04-02 DE DE60304327T patent/DE60304327T2/de not_active Expired - Lifetime
- 2003-04-02 NZ NZ535741A patent/NZ535741A/en not_active IP Right Cessation
- 2003-04-02 DK DK03730299T patent/DK1492792T3/da active
- 2003-04-02 AU AU2003240930A patent/AU2003240930B2/en not_active Ceased
- 2003-04-02 IL IL16425703A patent/IL164257A0/xx unknown
- 2003-04-02 JP JP2003580339A patent/JP4575670B2/ja not_active Expired - Fee Related
2004
- 2004-09-23 IL IL164257A patent/IL164257A/en not_active IP Right Cessation
- 2004-09-30 NO NO20044153A patent/NO329426B1/no not_active IP Right Cessation
- 2004-09-30 IS IS7478A patent/IS2483B/is unknown
- 2004-10-01 ZA ZA2004/07945A patent/ZA200407945B/en unknown
2006
- 2006-06-29 CY CY20061100885T patent/CY1104998T1/el unknown
2007
- 2007-05-16 US US11/749,342 patent/US7323467B2/en not_active Expired - Lifetime
- 2007-10-04 US US11/867,366 patent/US7405306B2/en not_active Expired - Fee Related
2008
- 2008-06-20 US US12/143,059 patent/US20080255129A1/en not_active Abandoned
2010
- 2010-06-22 JP JP2010141683A patent/JP5277208B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL164257A (en)	2009-11-18
FR2838124A1 (fr)	2003-10-10
US7235554B2 (en)	2007-06-26
JP5277208B2 (ja)	2013-08-28
HRP20040911B1 (en)	2012-11-30
WO2003082874A3 (fr)	2004-04-01
DE60304327D1 (de)	2006-05-18
US20050124615A1 (en)	2005-06-09
IL164257A0 (en)	2005-12-18
WO2003082874A2 (fr)	2003-10-09
MEP23708A (en)	2010-06-10
RS51244B (sr)	2010-12-31
HK1102371A1 (en)	2007-11-16
US7323467B2 (en)	2008-01-29
PT1492792E (pt)	2006-08-31
BR0309018A (pt)	2005-02-01
EP1492792B1 (de)	2006-03-29
CA2481460A1 (en)	2003-10-09
CN100406459C (zh)	2008-07-30
CN1656099A (zh)	2005-08-17
IS2483B (is)	2008-12-15
CN1970538A (zh)	2007-05-30
KR100975999B1 (ko)	2010-08-17
AU2003240930A1 (en)	2003-10-13
US20080255129A1 (en)	2008-10-16
HK1074632A1 (zh)	2005-11-18
EA007219B1 (ru)	2006-08-25
PL372617A1 (en)	2005-07-25
ES2261940T3 (es)	2006-11-16
NO329426B1 (no)	2010-10-18
NZ535741A (en)	2007-03-30
EA200401146A1 (ru)	2005-06-30
US20070219202A1 (en)	2007-09-20
EP1492792A2 (de)	2005-01-05
JP2010248221A (ja)	2010-11-04
US20080076775A1 (en)	2008-03-27
MXPA04009635A (es)	2005-07-13
DE60304327T2 (de)	2006-12-28
NO20044153L (no)	2004-12-27
CA2481460C (en)	2011-02-15
DK1492792T3 (da)	2006-08-14
US7405306B2 (en)	2008-07-29
AU2003240930B2 (en)	2009-07-30
RS86904A (sr)	2006-12-15
CN100543016C (zh)	2009-09-23
JP2005527566A (ja)	2005-09-15
FR2838124B1 (fr)	2004-05-28
ZA200407945B (en)	2005-11-30
ME00081B (me)	2010-10-10
UA77273C2 (en)	2006-11-15
JP4575670B2 (ja)	2010-11-04
IS7478A (is)	2004-09-30
KR20040094904A (ko)	2004-11-10
HRP20040911A2 (en)	2004-12-31
CY1104998T1 (el)	2009-11-04

Legal Events

Date

Code

Title

Description

2007-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1492792

Country of ref document: EP

Publication	Publication Date	Title
HRP20020712B1 (hr)	2012-11-30	Farmaceutske strukture koje sadrže derivate azetidina, novi derivati azetidina i njihovo pripremanje
ATE420862T1 (de)	2009-01-15	1,2-dihydropyridinverbindungen, verfahren zu deren herstellung und deren verwendung
DE60318583D1 (de)	2008-02-21	N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung
EP1371647A3 (de)	2004-07-28	Pyridin-3-carbonsäurederivate und ihre Verwendung als Zwischenprodukte
CY1106343T1 (el)	2011-10-12	Παραγωγα νικοτιναμιδιου χρησιμα σαν pde4 αναστολεις
IL125048A0 (en)	1999-01-26	Barbituric acid derivatives processes for their production and pharmaceutical agents containing these compounds
WO2005080357A3 (fr)	2005-12-15	Derives d’oxazole, leur preparation et leur utilisation en therapeutique
ATE321763T1 (de)	2006-04-15	3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino¬4, - bäindolacetamidderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
TW200607808A (en)	2006-03-01	Pyrido-pyrimidine derivatives, preparation thereof and application thereof
YU49902A (sh)	2005-03-15	Supstituisani derivati piperazina kao mtp inhibitori
CY1106029T1 (el)	2011-04-06	Παραγωγα 3-ετepοαρυλιο-3,5-διυδρο-4-οξο-4η-πυριδαζινο[4,5-β]ινδολη-1-καρβοξαμιδο, η παρασκευη τους και η εφαρμογη τους στη θepαπευτικη
CA2395969A1 (en)	2002-07-03	Novel tetrahydropyridines, method for the preparation thereof and pharmaceutical compositions containing them
WO2004009585A3 (fr)	2004-05-06	Derives d'acyloxypyrrolidine et leur utilisation en tant que ligands des recepteurs v1b et v1a de avp
NO20041704L (no)	2004-04-26	Substituerte alkylaminopyridazinonderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som inneholder disse
HK1042288A1 (zh)	2002-08-09	6-[[(芳基和雜芳基)氧]甲基]-萘基-2-甲亞胺酸酰胺衍生物，其製備方法及其在治療方面的應用
AU2002244985A1 (en)	2003-10-08	Thiazolidinedione derivatives and pharmaceutical composition comprising the same
UA72934C2 (uk)	2005-05-16	Феніл- і піридилтетрагідропіридини, що інгібують фактор некрозу пухлин, спосіб їх одержання та фармацевтична композиція
NO20064073L (no)	2006-11-06	Derivater fra 2H- eller 3H-benzo[e]indazol-1-yl-karbamat, deres fremstilling og terapeutisk anvendelse derav
NZ336032A (en)	2000-12-22	Diphenylalkyl-tetrahydropyridines and use in pharmaceutical compositions
DE60227506D1 (de)	2008-08-21	DIHYDROIMIDAZOi5,1-A -BETA-CARBOLIN-DERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE ANWENDUNG ALS ARZNEIMITTEL
MX2007003159A (es)	2007-05-16	Derivados piridinicos de indolin-2-ona, prepracion y uso terapeutico de los mismos.
GR1001123B (el)	1993-04-28	Μεθοδος παρασκευης 1,4-διυδροπυριδινων.
CO5631444A2 (es)	2006-04-28	Derivados 3-heteroaril-3,5-dihidro-4-oxo-4h-piridazino [4,5- b] indol-1-ecetamida
WO2001034576A3 (en)	2001-11-29	Use of pyrimidinone derivatives for controlling undesired microorganisms
AU2003253173A1 (en)	2005-03-16	Synthesis of 1-(4-(2-methoxyphenyl) piperazin-1-yl)-3-(2,6-dioxopiperidin-1-yl) propane